# PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USE

## Claims
Verbindung der Formel I

## Description
The present invention relates to compounds having antiviral activity, processes for their preparation and pharmaceutical compositions containing them. EP A 108285 The Wellcome Foundation Limited discloses purine derivatives having antiviral activity. The compound 9 4 hydroxy 3 hydroxymethylbut 1 yl guanine of formula A We have now prepared a series of analogues of the compound of formula A which has useful oral absorption properties and is converted According to the present invention there is provided a compound of formula I Acyl groups for R₁ and R₂ are those where the group R₁O or R₂O is a pharmaceutically acceptable carboxylic ester group which are As used herein the term aryl includes phenyl which may be optionally substituted with one or two groups selected from C₁ ₆ alkyl, C₁ ₆ alkoxy or halo such as fluoro or chloro. Preferably R₃ is methyl, ethyl, propyl, methoxy, or phenyl. Suitably when R₁ and R₂ are joined together, they A suitable example of a compound of formula I is the compound where one of R₁ or R₂ is In the case of compounds of formula I wherein one of R₁ or R₂ is an acyl or phosphate group, the compound exists in two enantiomeric forms. The invention includes both enantiomers in isolated form and mixtures thereof. The compounds of the invention may be in crystalline form or as hydrates and it is intended that both forms are encompassed by the expression compound of formula I used herein. Salts of the compound of formula I are preferably pharmaceutically acceptable, but non pharmaceutically acceptable salts are also within the scope of the present invention, since these are useful as intermediates in the preparation of pharmaceutically acceptable compounds. Examples of pharmaceutically acceptable salts of the compound of formula I are acid addition salts formed with a pharmaceutically acceptable acid such as hydrochloric acid,orthophosphoric acid and sulphuric acid. When the compound of formula I contains a phosphate group suitable salts include metal salts, such as aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy lower alkylamines such as 2 hydroxyethylamine, bis 2 hydroxyethyl amine or tri 2 hydroxyethyl amine. Suitable compounds of formula I include The compounds of the present invention are potentially useful in the treatment of infections caused by herpes viruses, such as herpes simplex type 1, herpes simplex type 2 and varicella zoster viruses. Accordingly, the present invention also provides a compound of formula I or a pharmaceutically acceptable salt thereof, for use as an active therapeutic substance and in particular for use in the treatment of viral infections. The compound of formula I wherein R₁ and R₂ are both hydrogen or a salt thereof may be prepared by hydrolysing the 1,3 dioxane ring of a compound of formula II Preferably the hydrolysis of the compound of formula II is carried out in acid medium, conveniently aqueous hydrochloric acid. The compound of formula II is itself an example of a compound of formula I and may be prepared by reducing a compound of formula III The reduction is preferably carried out catalytically, using palladium on charcoal, and the subsequent hydrolysis to the compound of formula I may be conveniently performed directly on the reaction product mixture. The intermediate compound of formula III may be prepared by treating a compound of formula IV The reaction may be carried out in an inert organic solvent, preferably dimethylformamide, in the presence of an inorganic base, preferably potassium carbonate. The compound of formula IV may itself be prepared by brominating a compound of formula VI The reaction is preferably carried out by treating the compound of formula VI with carbon tetrabromide and triphenylphosphine in an organic, aprotic solvent such as dimethylformamide. The compound of formula VI may itself be prepared by treating a compound of formula VII Compounds of formula I wherein R₁ and R₂ are acyl groups or are joined together to form a cyclic carbonate group can be prepared by reduction of a compound of formula VIII Suitable acyl groups for R₄ and R₅ include groups The reduction is suitably carried out under conditions described above for the reduction of a compound of formula III . Compounds of formula I wherein R₁ and R₂ are acyl groups can be converted to a compound of formula I wherein R₁ and or R₂ are hydrogen by conventional deacylation or partial deacylation processes. For example, reaction with methanolic ammonia can be used to effect complete deacylation to yield compound of formula I wherein both R₁ and R₂ are hydrogen. Reaction with a mild base such as potassium carbonate can result in partial deacylation to produce a compound of formula I wherein one of R₁ or R₂ is hydrogen and the other is an acyl group. Compounds of formula VIII , may be prepared by treating the compound of formula V as hereinbefore defined, with a compound of formula X The compound of formula V is a known compound. Compounds of formula X in which Z is bromine may be prepared by brominating a compound of formula XI . Compounds of formula X in which Z is Cl or I may be prepared in an analogous manner. Compounds of formula XI in which R₄ and R₅ are the same and are acyl groups may be prepared according to the following schematic process Suitably R₆ is a group removable by hydrolysis or hydrogenolysis. Preferably R₆ is a group removable by hydrogenolysis such as benzyl. This group can be removed by conventional methods for example by using hydrogen in the presence of a palladium carbon catalyst. Compounds of formula XI wherein R₄ and R₅ are joined together to form a cyclic carbonate group may be prepared by reaction of a compound formula XII The above described processes for preparing the compound of formula III and compounds of formula VIII are also disclosed in Published European European Patent Application No. 0141 927. Compounds of formula I wherein R₁ and or R₂ is acyl may be prepared by esterifying a compound of formula I wherein R₁ and R₂ is hydrogen by conventional methods. If necessary during the esterification process the NH₂ group and optionally also one of the OR₁,or OR₂ groups may be protected by a suitable protecting group such as trityl or monomethoxytrityl. The product is subsequently deprotected for example by treatment with acid such as acetic acid. For example, compounds of formula I wherein R₁O and or R₂O is a carboxylic ester group may be prepared by reaction of a compound of formula I which has been optionally protected as described above with a , an appropriate carboxylic acid chloride or b an appropriate carboxylic acid anhydride or c an appropriate carboxylic acid in the presence of a dehydrating agent such as dicyclohexylcarbodiimide DCCI . Compounds of formula I wherein R₁ and R₂ form a cyclic carbonate group can be prepared by reaction of a compound of formula I wherein R₁ and R₂ are hydrogen and the NH₂ group is optionally protected with phosgene or 1,1 carbonyldiimidazole, and thereafter if necessary deprotecting the product. Suitable protecting groups for the NH₂ group include trityl and monomethoxytrityl as described above. The reaction is suitably carried out in a dry organic solvent such as pyridine at a temperature of from 0 50 C, conveniently at ambient temperature. Compounds of formula I wherein one of R₁ or R₂ is phosphate or R₁ and R₂ together form a cyclic phosphate can be prepared by treating a compound formula XIII A suitable phosphorylating agent is phosphorus oxychloride, optionally in the presence of a base such as pyridine. In addition, when one of R₈ or R₉ is a protecting group cyanoethyl phosphoric acid can be employed as a phosphorylating agent in order to produce a compound of formula I wherein one of R₁ or R₂ is phosphate. The reaction product after treatment with cyanoethyl phosphoric acid is treated with aqueous ammonia, which yields the ammonium salt of the phosphate ester as the final product. Compounds of formula XIII can be prepared by protection of a compound of formula I wherein R₁ and R₂ is hydrogen, for example by reaction with a trityl or monomethoxytrityl halide such as monomethoxytrityl chloride. Alternatively compounds of formula I wherein R₁ and R₂ are joined together to form a cyclic phosphate can be prepared from a compound of formula I wherein one of R₁ or R₂ is phosphate and the other is hydrogen by cyclisation of the monophosphate for example using dicyclohexylcarbodiimide. Compounds of formula I wherein one of R₁ or R₂ is acyl and the other is hydrogen or R₁ and R₂ together form a cyclic acetal can be prepared by reacting a compound of formula I wherein R₁ and R₂ are hydrogen with a compound of formula XIV wherein When a compound of formula I in which R₁ and R₂ is a cyclic acetal is required, a compound of formula XIV wherein m is 2 and n is 2 is employed. For example, when m is 2, n is 2 and R₁₀ is methyl, the product is the compound of formula II as hereinbefore defined. The reaction is suitably carried out in an inert organic solvent such as tetrahydrofuran or N,N dimethylformamide, in the presence of an acid such as p toluene sulphonic acid. Where necessary the subsequent hydrolysis step is an aqueous hydrolysis preferably carried out in the presence of an acid such as p toluene sulphonic acid. Compounds of formula XIV are known compounds or can be prepared from known compounds by known methods. Compounds of formula I or pharmaceutically acceptable salts thereof may be formulated for use in a pharmaceutical composition. Accordingly, in a further aspect of the invention, there is provided a pharmaceutical composition which comprises a compound of formula I or pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or excipient. A composition which may be administered by the oral route to humans may be compounded in the form of a syrup, tablet or capsule. When the composition is in the form of a tablet, any pharmaceutical carrier suitable for formulating such solid compositions may be used, for example magnesium stearate, starch, lactose, glucose, rice, flour and chalk. The composition may also be in the form of an ingestible capsule, for example of gelatin, to contain the compound, or in the form of a syrup, a solution or a suspension. Suitable liquid pharmaceutical carriers include ethyl alcohol, glycerine, saline and water to which flavouring or colouring agents may be added to form syrups. The compounds may also be presented with a sterile liquid carrier for injection. The composition may also be formulated for topical application to the skin or eyes. For topical application to the skin, the composition may be in the form of a cream, lotion or ointment. These formulations may be conventional formulations well known in the art, for example, as described in standard books of pharmaceutics and cosmetics, such as Harry s Cosmeticology published by Leonard Hill Books and the British Pharmacopaeia. The composition for application to the eyes may be a conventional eye drop composition well known in the art, or an ointment composition. Preferably, the composition of this invention is in unit dosage form or in some other form that the patient may administer to himself a single dose. A suitable dosage unit might contain from 50 mg to 1 g of active ingredient, for example 100 to 500 mg. Such doses may be administered 1 to 4 times a day or more usually 2 or 3 times a day. The effective dose of compound will in general be in the range of from 1.0 to 20 mg kg of body weight per day or more usually 2.0 to 10 mg kg per day. No toxicological effects are indicated at the above described dosage levels. In a further aspect of the invention there is provided the use of a compound of formula I or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of viral infections. The following examples illustrate the invention. To a solution of 2 amino 6 chloro 9 2 2,2 dimethyl 1, 3 dioxan 5 yl ethyl purine 0.54g, 1.75mmol in ethanol 10ml and cyclohexene 20ml was added 10 palladium on charcoal 400mg and the solution was refluxed for 7 hours. A further quantity of catalyst 200mg was added and the solution was refluxed overnight. The solution was filtered and washed through with methanol. To the filtrate was added hydrochloric acid 5 To a solution of ammonium formate in methanol 400m A suspension of 9 4 acetoxy 3 acetoxymethylbut 1 yl 2 amino 6 chloropurine 0.36g, 1.0mmol and 10 palladium on charcoal 30mg in methanol containing ammonium formate 400m To a suspension of 9 4 acetoxy 3 acetoxymethylbut 1 yl 2 amino 6 chloropurine 4.86g, 13.7mmol in methanol 140ml containing ammonium formate 400m To a solution of 9 4 acetoxy 3 acetoxymethylbut 1 yl 2 aminopurine 0.48g, 1.5mmol in methanol 9ml was added anhydrous potassium carbonate 14mg, 0.1mmol and the solution was stirred for 20 minutes. Two drops of glacial acetic acid were added, the solution was filtered and the solvent was removed. The residue was purified by column chromatography on silica gel eluting with chloroform methanol 15 1, 10 1 to afford 9 4 acetoxy 3 hydroxymethyl 1 yl 2 aminopurine as a white crystalline solid 124mg, 30 , m.p. 166 168 ν To a suspension of 2 amino 9 4 hydroxy 3 hydroxymethylbut 1 yl purine 237mg, 1.0mmol in dry tetrahydrofuran 3ml were added To a suspension of 2 amino 9 4 hydroxy 3 hydroxymethylbut 1 yl purine 240mg, 1.0mmol in N,N dimethylformamide 3ml were added A solution of 2 amino 9 4 hydroxy 3 hydroxymethylbut 1 yl purine 0.21g, 0.9mmol , 4 dimethylaminopyridine 10mg and propionic anhydride 0.64ml, 5.0mmol in N,N dimethylformamide 5ml was stirred for 16 hours. The solvent was removed and the residue was partitioned between aqueous sodium bicarbonate and chloroform. The organic layer was dried magnesium sulphate and the solvent was removed. The residue was purified by column chromatography on silica gel eluting with chloroform methanol 20 1 to give 2 amino 9 4 propionyloxy 3 propionyloxymethylbut 1 yl purine 160mg, 51 which was recrystallised from ethyl acetate hexane 115mg, 37 , m.p. 77.5 79 λ To a suspension of 2 amino 9 4 hydroxy 3 hydroxymethylbut 1 yl purine 2.37g, 10mmol in N,N dimethylformamide 40ml containing 4 dimethylaminopyridine 30mg and triethylamine 4.2ml was added a solution of monomethoxytrityl chloride 6.8g, 22mmol in N,N dimethylformamide 60ml over a period of 40 minutes. The solution was stirred for a further 40 minutes, methanol 1ml was added and the solvent was removed. The residue was taken up in chloroform and washed with water and dilute aqueous sodium bicarbonate. The organic layer was dried magnesium sulphate and the solvent was removed. The residue was purified by column chromatography on silica gel eluting with chloroform methanol mixtures 40 1 to 6 1 . The first product to elute was 9 3 hydroxymethyl 4 monomethoxytrityloxybut 1 yl 2 monomethoxytritylaminopurine which was further purified by a second silica gel column eluting with chloroform methanol 40 1 and obtained as a colourless foam 3.34g, 43 λ The second product to elute was 9 4 hydroxy 3 hydroxymethylbut 1 yl 2 monomethoxytritylaminopurine which was obtained as a white crystalline solid after trituration and filtration from ether 2.07g, 41 , m.p. 181 183 λ To a solution of 9 3 hydroxymethyl 4 monomethoxytrityloxybut 1 yl 2 monomethoxytritylaminopurine 0.70g, 0.9mmol and 4 dimethylaminopyridine 10mg in N,N dimethylformamide 5ml was added butyric anhydride 0.29ml, 1.8mmol and the solution was stirred for 15 minutes. Methanol 1ml was added and the solvent was removed. The residue was taken up in 80 acetic acid 9ml and the solution was stirred at 70 for 30 minutes. Water 2ml was added and the solution was extracted with hexane 2 x 10ml . The aqueous layer was retained and the solvent was removed. The residue was partitioned between saturated aqueous sodium bicarbonate and chloroform and the organic layer was dried magnesium sulphate and the solvent removed. The residue was purified by column chromatography on silica gel eluting with chloroform methanol 16 1 to afford 2 amino 9 4 butyryloxy 3 hydroxymethylbut 1 yl purine which was obtained as a white crystalline solid after trituration with methanol 188mg, 68 , m.p. 125 127 λ To a solution of 9 3 hydroxymethyl 4 monomethoxytrityloxybut 1 yl 2 monomethoxytritylaminopurine 0.70g, 0.9mmol and 4 dimethylaminopyridine 10mg in N,N dimethylformamide 5ml was added benzoic anhydride 0.61g, 2.7mmol and the solution was stirred for 1 hour. Methanol 1ml was added and the solvent was removed. The residue was taken up in 80 acetic acid 9ml and the solution was stirred at 80 for 20 minutes. Water 3ml was added and the solution was extracted with hexane 2 x 10ml . The aqueous layer was retained and the solvent was removed. The residue was partitioned between saturated aqueous sodium bicarbonate and chloroform and the organic layer was dried magnesium sulphate and the solvent removed. The residue was purified by column chromatography on silica gel eluting with chloroform methanol 14 1 to afford 2 amino 9 4 benzoyloxy 3 hydroxymethylbut 1 yl purine which was obtained as a white crystalline solid after trituration with methanol 235mg, 76 , m.p. 116 118 λ To an ice cooled solution of phosphorus oxychloride 0.10ml, 1.1mmol in pyridine 2ml was added dropwise over 15 minutes a solution of 9 3 hydroxymethyl 4 monomethoxytrityloxybut 1 yl 2 monomethoxytritylaminopurine 0.78g, 1.0mmol in pyridine 2ml . The solution was stirred for a further 5 minutes at 0 and then for 30 minutes at room temperature. The solution was added dropwise to a solution of sodium bicarbonate 0.5g, 6.0mmol in water 7ml . The solvent was removed and the residue was taken up in 80 acetic acid 10ml and the solution was stirred at 70 for 25 minutes. The solvent was removed and the residue was taken up in water and brought to pH 6 by addition of ammonia. The solution was extracted twice with chloroform and the solvent was removed. The residue was purified by preparative high pressure liquid chromatography on a C₁₈ reverse phase µ Bondapack column eluting with 3 methanol in ammonium acetate buffer pH 4.5, 50m To an ice cooled solution of phosphorus oxychloride 93µl, 1.0mmol in pyridine 2ml was added dropwise over 45 minutes a solution of 9 4 hydroxy 3 hydroxymethylbut 1 yl 2 monomethoxytritylaminopurine 0.46g, 0.9mmol in pyridine 4ml . The solution was stirred for a further 20 minutes at room temperature and was then added dropwise to a solution of sodium bicarbonate 0.34g, 4.0mmol in water 6ml . The solvent was removed and the residue was taken up in 80 acetic acid 9ml and the solution was stirred at 70 for 25 minutes. The solvent was removed and the residue was taken up in water and brought to pH 6 by addition of ammonia. The solution was extracted twice with chloroform and the solvent was removed. The residue was purified by preparative high pressure liquid chromatography on a C₁₈ reverse phase µ Bondapack column eluting with 4 methanol in ammonium acetate buffer pH 4.5, 50m To an aqueous solution of 2 amino 9 4 hydroxy 3 hydroxymethylbut 1 yl purine 0.5m Incubation of 9 4 hydroxy 3 hydroxymethylbut 1 yl guanine with xanthine oxidase under identical conditions resulted in no change over a 2 hour period. 2 Amino 9 4 hydroxy 3 hydroxymethylbut 1 yl purine, 2 amino 9 4 acetoxy 3 acetoxymethylbut 1 yl purine and 9 4 hydroxy 3 hydroxymethylbut 1 yl guanine were administered by oral gavage 0.2mmoles kg in 0.1ml of 1 carboxymethyl cellulose to 20g female Balb C mice which had been starved for 18 hours. Fifteen 60 and 180 minutes later, blood was collected from three mice per time point by cardiac puncture using heparinised syringes. Equal aliquots at each time were pooled and an equal volume of 16 trichloroacetic acid added. Following centrifugation 8,500g to remove precipitated proteins, 0.5ml of supernatant was immediately added to 0.1ml of saturated sodium bicarbonate solution and the resulting mixture analysed by high performance liquid chromatography or stored at 20 C prior to analysis.